Exact Sciences, Guardant rally after Freenome colorectal cancer test results

Shares of Exact Sciences (EXAS) and Guardant Health (GH) are moving higher after privately held Freenome announced topline results from PREEMPT CRC, a clinical study to validate the company’s blood-based test for the early detection of colorectal cancer among average-risk adults.